Anti-hepatitis B viral activity of Phyllanthus niruri L (Phyllanthaceae) in HepG2/C3A and SK-HEP-1 cells
Purpose: To investigate the effectiveness of an ethanol extract of Phyllanthus niruri against hepatitis B viral (HBV) infection in human HepG2/C3A cells.
Methods: An ellagic acid-rich ethanol fraction was obtained from P. niruri (Euphorbiaceae) by extraction and thin-layer chromatography. The anti-HBV activity of the fraction was evaluated in vitro against HepG2/C3A cells. The physicochemical characteristics of the fraction were assessed by nuclear magnetic resonance (1H and 12C-NMR).
Results: The isolated active compound showed a half-maximal inhibitory concentration (IC50) of 120 μg/mL. Ellagic acid had no effect on HBV DNA replication at the concentrations evaluated, and did not inhibit the reproduction of HBV. However, the ethanol fraction inhibited the growth of HBV-infected HepG2/C3A cells.
Conclusion: The findings suggest that the ethanol fraction of P. niruri inhibits HBV, and that the active component is not ellagic acid.
Keywords: Phyllanthus niruri, Anti-HBeAg, Hepatitis B virus
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.